Adenowrus-mediated anti-K-ras ribozyme induces apoptosis and growth suppression of human pancreatic carcinoma

Cancer Gene Therapy

Volumn 7, Issue 3, 2000, Pages 373-383

  Tsuchida, Takashi ^a   Kijima, Hiroshi ^a   Hori, Sadaaki ^a   Oshika, Yoshiro ^a   Tokunaga, Tetsuji ^a   Kawai, Kenji ^a   Yamazaki, Hitoshi ^a   Ueyama, Yoshito ^a,b   Scanlon, Kevin J ^c   Tamaoki, Norikazu ^a   Nakamura, Masato ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

^c BAYER AG   (Germany)

Author keywords

Apoptosis; K ras oncogene; Pancreatic carcinoma; Recombinant adenovirus; Ribozyme

Indexed keywords

RIBOZYME; VIRUS VECTOR; ANTINEOPLASTIC AGENT; GROWTH INHIBITOR; HRAS PROTEIN, HUMAN; MESSENGER RNA; PROTEIN P21;

ADENOVIRUS; APOPTOSIS; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; NONHUMAN; ONCOGENE; ONCOGENE K RAS; PANCREAS CARCINOMA; PRIORITY JOURNAL; VIRUS RECOMBINANT; CELL CULTURE; CELL FREE SYSTEM; DRUG ANTAGONISM; ENZYMOLOGY; GENE TRANSFER; GENETIC RECOMBINATION; GENETICS; HYDROLYSIS; METABOLISM; MOLECULAR CLONING; PANCREAS TUMOR; PATHOLOGY; PLASMID; SITE DIRECTED MUTAGENESIS; SYNTHESIS; ULTRASTRUCTURE;

ADENOVIRIDAE;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL-FREE SYSTEM; CLONING, MOLECULAR; GENE TRANSFER TECHNIQUES; GROWTH INHIBITORS; HUMANS; HYDROLYSIS; MUTAGENESIS, SITE-DIRECTED; PANCREATIC NEOPLASMS; PLASMIDS; PROTO-ONCOGENE PROTEINS P21(RAS); RECOMBINATION, GENETIC; RNA, CATALYTIC; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0033624988     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700136     Document Type: Article

References (59)

1. Urrutia R, DiMagno EP. Genetic marker: the key to early diagnosis and improved survival in pancreatic cancer? Gastroenterology. 1997;110:306-310.
2. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med. 1992;326:455-456.
3. Barbacid M. ras genes. Annu Rev Biochem. 1987;56:779-827.
4. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682-4689.
5. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988;53:549-554.
6. Smit VTHBM, Boot AJM, Smit AMM, Fleuren GJ, Cornelisse CJ, Bos JL. Kras codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res. 1988;16:7773-7782.
7. Grunewald K, Lyons J, Frohlich A, et al. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer. 1989;43:1037-1041.
8. Tada M, Yokosuka O, Omata M, Ohio M, Isono K. Analysis of ras gene mutations in biliary and pancreatic tumors by polymerase chain reaction and direct sequencing. Cancer. 1990;66:930-935.
9. Yanagisawa A, Ohtake K, Ohashi K, et al. Frequent c-K-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res. 1993;53:953-956.
10. DiGiuseppe JA, Hruban RH, Offerhaus GJ, et al. Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. Am J Pathol. 1994;144:889-895.
11. Tada M, Ohashi M, Shiratori Y, et al. Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology. 1997;110: 227-231.
12. Kashani-Sabet M, Scanlon KJ. Application of ribozymes to cancer gene therapy. Cancer Gene Ther. 1995;2:213-221.
13. Christoffersen RE, Mar JJ. Ribozymes as human therapeutic agents. J Med Chem. 1995;38:2023-2037.
14. Helene C. Control of oncogene expression by antisense nucleic acids. Eur J Cancer. 1994;30A:1721-1726.
15. Scanlon KJ, Ohta Y, Ishida H, et al. Oligonucleotide-mediated modulation of mammalian gene expression. FASEB J. 1995;6:1288-1296.
16. Mercola D, Cohen JS. Antisense approach to cancer gene therapy. Cancer Gene Ther. 1995;2:47-59.
17. Castanotto D, Rossi JJ, Sarver N. Antisense catalytic RNAs as therapeutic agents. Adv Pharmacol. 1994;25:289-317.
18. Kijima H, Ishida H, Ohkawa T, Kashani-Sabet M, Scanlon KJ. Therapeutic applications of ribozymes. Pharmacol Ther. 1995;68:247-267.
19. Irie A, Kijima H, Ohkawa T, et al. Anti-oncogene ribozymes for cancer gene therapy. Adv Pharmacol. 1997;40: 207-257.
20. Symons RH. Ribozymes. Curr Opin Struct Biol. 1994;4: 322-330.
21. Pley HW, Flaherty KM, McKay DB. Three-dimensional structure of a hammerhead ribozyme. Nature. 1994;372: 68-74.
22. Uhlenbeck OC. A small catalytic oligonucleotide. Nature. 1987;328:596-600.
23. Scanlon KJ, Jiao L, Funato T, Wang W, Tone T, Rossi JJ, Kashani-Sabet M. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci USA. 1991;88:10591-10595.
24. Funato T, Shitara T, Tone T, Jiao L, Kashani-Sabet M, Scanlon KJ. Suppression of H-ras-mediated transformation in NIH3T3 cells by a ras ribozyme. Biochem Pharmacol. 1994;48:1471-1475.
25. Ohta Y, Kijima H, Kashani-Sabet M, Scanlon KJ. Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes. J Invest Dermatol. 1996;106:275-280.
26. Snyder DS, Wu Y, Wang JL, et al. Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood. 1993;82:600-605.
27. Leopold LH, Shore SK, Newkirk TA, Reddy RMV, Reddy EP. Multi-unit ribozyme mediated cleavage of bcr-abl mRNA in myeloid leukemia. Blood. 1995;85:2162-2170.
28. Scanlon KJ, Ishida H, Kashani-Sabet M. Ribozyme-mediated reversal of the multidrug-resistant phenotype. Proc Natl Acad Sci USA. 1994;91:11123-11127.
29. Kobayashi H, Dorai T, Holland JF, Ohnuma T. Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme. Cancer Res. 1994;54:1271-1275.
30. Sarver N, Cantin EM, Chang PS, et al. Ribozymes as potential anti-HIV-1 therapeutic agents. Science. 1990; 247:1222-1225.
31. Yu M, Ojwang J, Yamada O, et al. A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type-1. Proc Natl Acad Sci USA. 1993;87: 6340-6344.
32. Kashani-Sabet M, Funato T, Tone T, et al. Reversal of the malignant phenotype by an anti-ras ribozyme. Antisense Res Dev. 1992;2:3-15.
33. Tone T, Kashani-Sabet M, Funato T, et al. Suppression of EJ cells tumorigenicity. In Vivo. 1993;7:471-476.
34. Kashani-Sabet M, Funato T, Florenes VA, Fodstad O, Scanlon KJ. Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme. Cancer Res. 1994;54:900-902.
35. Feng M, Cabrera G, Deshane J, Scanlon KJ, Curiel DT. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res. 1995;55:2024-2028.
36. Ohta Y, Tone T, Shitara T, et al. H-ras ribozyme-mediated alteration of the human melanoma phenotype. Ann N Y Acad Sci. 1994;716:242-253.
37. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd ed. New York: Cold Spring Harbor Laboratory Press; 1989.
38. Yamazaki H, Kijima H, Ohnishi Y, et al. Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression. J Natl Cancer Inst. 1998;90:581-587.
39. Becker TC, Noel RJ, Coats WS, et al. Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol. 1994;43:161-189.
40. Graham FL, Prevec L. Manipulation of adenovirus vectors. Methods Mol Biol. 1991;7:109-128.
41. Lee F-JS, Moss J, Lin LW. A simplified procedure for hybridization of RNA blots. Biotechniques. 1992;13:130-132.
42. Kanegae Y, Makimura M, Saito I. A simple method for purification of infectious recombinant adenovirus. Jpn J Med Sci Biol. 1994;47:157-166.
43. Kuroki T. Agar plate culture and Lederberg-style replica plating of mammalian cells. Methods Cell Biol. 1978;9:157-178.
44. Aoki K, Yoshida T, Sugimura T, Terada M. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res. 1995;55:3810-3816.
45. Zhang Y, Mukhopadhyay T, Donehower LA, Georges RN, Roth JA. Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer inhibits expression of the malignant phenotype. Hum Gene Ther. 1993;4:451-460.
46. Georges RN, Mukhopadhyay T, Zhang Y, Yen N, Roth JA. Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res. 1993;53:1743-1746.
47. Dolnikov A, King A, Luxford C, Symonds G, Sun L-Q. Ribozyme-mediated suppression of v-myc expression abrogates apoptosis in transformed monocytes. Cancer Gene Ther. 1996;3:289-295.
48. Wang J, Buccana CD, Roth JA, Zang W-W. Apoptosis induced in human osteosarcoma cells is one of the mechanisms for the cytocidal effect of Ad5CMV-p53. Cancer Gene Ther. 1995;2:9-17.
49. Sanding V, Brand K, Herwig S, Lukas J, Bartek J, Strauss M. Adenovirally transferred p16 INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med. 1997;3:313-319.
50. Zang W-W, Fang X, Mazur W, French BA, Georges RN, Roth JA. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther. 1994;1:5-13.
51. Ragot T, Vincent N, Chafey P, et al. Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. Nature. 1993;361:647-650.
52. Herz J, Gerard RD. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci USA. 1993;90:2812-2816.
53. Kinoshita T, Yokota T, Arai K, Miyajima A. Regulation of bcl-2 expression by oncogenic Ras protein in hematopoietic cells. Oncogene. 1995;10:2207-2212.
54. Ward RL, Todd AV, Satiago F, O'Connor T, Hawkins NJ. Activation of the K-ras oncogene in colorectal neoplasms is associated with decreased apoptosis. Cancer. 1997;79: 1106-1113.
55. Sanchez-Garcoa I, Martin-Zanca D. Regulation of bcl-2 gene expression by bcr-abl is mediated by ras. J Mol Biol. 1997;267:225-228.
56. Ohta Y, Kijima H, Kashani-Sabet M, Scanlon KJ. Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells. Nucleic Acids Res. 1996;24:938-942.
57. Lan K-H, Kanai F, Shiratori Y, et al. In vivo selective gene expression and therapy mediated by adenoviral vectors for human carcinoembryonic antigen-producing gastric carcinoma. Cancer Res. 1997;57:4279-4284.
58. Schrewe H, Thompson J, Bona M, et al. Cloning of the complete gene for carcinoembryonic antigen: analysis of its promoter indicates a region conveying cell type-specific expression. Mol Cell Biol. 1990;10:2738-2748.
59. Hauck W, Stanners CP. Transcriptional regulation of the carcinoembryonic antigen gene. J Biol Chem. 1995;270: 3602-3610.